New hope for lymphoma patients who Can't handle standard chemo
NCT ID NCT01679119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another common combination. The goal was to see which works better and is safer for these patients, with 129 participants taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aintree University Hospital
Liverpool, United Kingdom
-
Beatson West of Scotland Cancer Centre (including Gartnavel Royal Hospital)
Glasgow, United Kingdom
-
Bristol Oncology Centre
Bristol, United Kingdom
-
Castle Hill Hospital
Cottingham, United Kingdom
-
Christie Hospital
Manchester, United Kingdom
-
Churchill Hospital
Oxford, United Kingdom
-
Darent Valley Hospital
Dartford, United Kingdom
-
Derriford Hospital
Plymouth, United Kingdom
-
Freeman Hospital
Newcastle, United Kingdom
-
Guy's Hospital (including St Thomas's Hospital)
London, United Kingdom
-
James Paget University Hospital
Great Yarmouth, United Kingdom
-
Kent and Canterbury Hospital
Canterbury, United Kingdom
-
Kettering General Hospital
Kettering, United Kingdom
-
Kings Mill Hospital
Sutton in Ashfield, United Kingdom
-
Leicester Royal Infirmary
Leicester, United Kingdom
-
Luton and Dunstable Hospital
Luton, United Kingdom
-
Medway Maritime Hospital
Gillingham, United Kingdom
-
Norfolk and Norwich University Hospital
Norwich, United Kingdom
-
North Hampshire Hospital
Basingstoke, United Kingdom
-
North Tyneside Hosptial (including Wansbeck Hospital and Hexham General Hospital)
North Shields, United Kingdom
-
Northwick Park Hospital
Harrow, United Kingdom
-
Nottingham City Hospital
Nottingham, United Kingdom
-
Princess Royal University Hospital
Orpington, United Kingdom
-
Queen's Hospital
Romford, United Kingdom
-
Royal Bournemouth Hospital
Bournemouth, United Kingdom
-
Royal Cornwall Hospital
Truro, United Kingdom
-
Royal Devon & Exeter Hospital
Exeter, United Kingdom
-
Royal Free Hospital
London, United Kingdom
-
Royal Hampshire County Hospital
Winchester, United Kingdom
-
Royal Liverpool University Hospital
Liverpool, United Kingdom
-
Royal United Hospital
Bath, United Kingdom
-
Southampton General Hospital
Southampton, United Kingdom
-
St James's University Hospital
Leeds, United Kingdom
-
Stoke Mandeville Hospital (including Wycombe Hospital)
Aylesbury, United Kingdom
-
Torbay Hospital
Torquay, United Kingdom
-
University College London Hospital
London, United Kingdom
-
University Hospital, Coventry
Coventry, United Kingdom
-
West Suffolk Hospital
Bury St Edmunds, United Kingdom
-
Worcester Royal Hospital (including Kidderminster Hospital and Alexandra Hospital)
Worcester, United Kingdom
-
Wythenshawe Hospital (including Trafford General Hospital)
Wythenshawe, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers